Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

Rebecca M Richards, MDPhD, Feifei Zhao, Katherine A Murphy, Peng Xu, MD, Amy Fan, Elena Sotillo, PhD, Mads Daugaard, Htoo Zarni Oo, Jie Liu, Wan-Jen Hong, Poul Sorensen, Robbie G. Majzner, MD, Ravi Majeti, MD PhD, Crystal L. Mackall, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-133988

Published: 2020

Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139605

Published: 2020

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Liora M Schultz, MD, Shabnum Patel, PhD, Sneha Ramakrishna, MD, Alice Bertaina, MD PhD, Neehar Bhatia, Jean Oak, MD PhD, Robbie G. Majzner, MD, Christina Baggott, RN, PhD, Kara L. Davis, DO, Crystal L. Mackall, MD, Steven A Feldman, PhD

Blood (2019) 134 (Supplement_1): 4471.

https://doi.org/10.1182/blood-2019-129436

Published: 2019

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

NARROW

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Email alerts

ASH Publications

American Society of Hematology

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only